Johnson & Johnson’s (JNJ) Buy (B) Rating Reiterated at Weiss Ratings

Weiss Ratings reaffirmed their buy (b) rating on shares of Johnson & Johnson (NYSE:JNJ) in a research report sent to investors on Friday morning,Weiss Ratings reports.

Other equities analysts have also issued reports about the stock. Piper Sandler reissued an “overweight” rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Loop Capital set a $190.00 price objective on shares of Johnson & Johnson in a report on Wednesday, October 22nd. Citigroup raised their target price on shares of Johnson & Johnson from $213.00 to $215.00 and gave the company a “buy” rating in a research note on Wednesday, October 15th. Guggenheim upgraded shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price objective for the stock from $167.00 to $206.00 in a research note on Tuesday, September 23rd. Finally, Raymond James Financial lifted their price objective on shares of Johnson & Johnson from $174.00 to $209.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 15th. Three investment analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have given a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average target price of $199.05.

Johnson & Johnson Stock Performance

Shares of NYSE:JNJ opened at $189.02 on Friday. The firm has a market cap of $455.40 billion, a PE ratio of 18.25, a price-to-earnings-growth ratio of 2.19 and a beta of 0.40. The firm’s 50 day simple moving average is $183.28 and its 200-day simple moving average is $167.75. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.48. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings data on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. The company had revenue of $24.02 billion for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 32.73%. As a group, equities analysts predict that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be issued a $1.30 dividend. The ex-dividend date of this dividend is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.8%. Johnson & Johnson’s payout ratio is presently 50.19%.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.16% of the company’s stock.

Institutional Trading of Johnson & Johnson

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Tandem Financial LLC purchased a new stake in shares of Johnson & Johnson during the third quarter worth about $219,000. Flagstone Financial Management purchased a new stake in shares of Johnson & Johnson during the third quarter worth about $206,000. Bank of Jackson Hole Trust increased its stake in shares of Johnson & Johnson by 9.9% during the third quarter. Bank of Jackson Hole Trust now owns 10,945 shares of the company’s stock worth $2,029,000 after purchasing an additional 983 shares in the last quarter. Chilton Capital Management LLC increased its stake in shares of Johnson & Johnson by 44.0% during the third quarter. Chilton Capital Management LLC now owns 22,624 shares of the company’s stock worth $4,195,000 after purchasing an additional 6,908 shares in the last quarter. Finally, Alta Advisers Ltd increased its stake in shares of Johnson & Johnson by 1.3% during the third quarter. Alta Advisers Ltd now owns 11,968 shares of the company’s stock worth $2,219,000 after purchasing an additional 150 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.